Search research articles
Contact Us
Filters
Showing results (101-110 of 211) with videos related to
Page
of 22
Sort By:
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Advances in Therapy
|
March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Leukemia Research Reports
|
October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Aurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Haematologica
|
December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Bruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, et al.
Seminars in Hematology
|
December 4, 2018
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
Felipe de Arriba de la Fuente, Maria Soledad Durán, Miguel Ángel Álvarez, et al.
Leukemia
|
January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study
Noffar Bar, Thomas Martin, Craig C Hofmeister, et al.
Haematologica
|
July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Pellegrino Musto, Monika Engelhardt, Jo Caers, et al.
The New England Journal of Medicine
|
August 30, 2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
Page
of 22
Search research articles
Search
Showing results (101-110 of 211) with videos related to
Sort By:
Page
of 22
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Advances in Therapy
|
March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Leukemia Research Reports
|
October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Aurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Haematologica
|
December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Bruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, et al.
Seminars in Hematology
|
December 4, 2018
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
Felipe de Arriba de la Fuente, Maria Soledad Durán, Miguel Ángel Álvarez, et al.
Leukemia
|
January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study
Noffar Bar, Thomas Martin, Craig C Hofmeister, et al.
Haematologica
|
July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Pellegrino Musto, Monika Engelhardt, Jo Caers, et al.
The New England Journal of Medicine
|
August 30, 2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
Page
of 22